Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C

Chronic hepatitis C is a common cause of liver-related morbidity and mortality. Ledipasvir/sofosbuvir is a combination of 2 direct-acting antiviral agents that has been approved for use in patients with genotype 1, 4, 5, or 6. This approval is based on multiple phase 3 studies in which the rate of s...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Medicine Insights: Therapeutics 2017-06, Vol.2017 (9), p.1-6-012
Main Authors: Childs-Kean, Lindsey M, Jourjy, Jacqueline
Format: Article
Language:English
Subjects:
Antiviral drugs
Authorship
Dosage and administration
Drug dosages
Drug therapy
Genotype & phenotype
Hepatitis
Hepatitis C
Hepatitis C virus
HIV
Human immunodeficiency virus
Infectious diseases
Liver diseases
Patients
Peer review
Sofosbuvir
Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-a456t-3d89e9c752ab32f305cccc07e7cb02b920e5eed323fa77a33dd18c42a04457313
container_end_page 6-012
container_issue 9
container_start_page 1
container_title Clinical Medicine Insights: Therapeutics
container_volume 2017
creator Childs-Kean, Lindsey M
Jourjy, Jacqueline
description Chronic hepatitis C is a common cause of liver-related morbidity and mortality. Ledipasvir/sofosbuvir is a combination of 2 direct-acting antiviral agents that has been approved for use in patients with genotype 1, 4, 5, or 6. This approval is based on multiple phase 3 studies in which the rate of sustained virologic response exceeded 90% for 12 or 24 weeks of treatment, depending on the patient population. For some patients, the addition of ribavirin is required. Ledipasvir/sofosbuvir is well tolerated, with the most commonly reported adverse events being fatigue and headaches.
doi_str_mv 10.1177/1179559X17719125
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2112956668</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A498584452</galeid><airiti_id>P20160603001_201712_201808230015_201808230015_1_6_012</airiti_id><sage_id>10.1177_1179559X17719125</sage_id><sourcerecordid>A498584452</sourcerecordid><originalsourceid>FETCH-LOGICAL-a456t-3d89e9c752ab32f305cccc07e7cb02b920e5eed323fa77a33dd18c42a04457313</originalsourceid><addsrcrecordid>eNp9UVGL1DAQLqLgcd67jwXBt95NkiZtHhSORT1hQcETfAvTdHqbo23WJCv4703p4d4eYgKZL1--bybJFMVrBpeMNc1VXrSU-kfGTDMunxVnC1Ut3PNH-GVxEeM9AHBeKyX0WfFuS73bY_zlwtU3P_jYHTIs3VymHZW3gTBNNKfSD-VmF_zsbHlDe0wuuVhuXhUvBhwjXTzE8-L7xw-3m5tq--XT5831tsJaqlSJvtWkbSM5doIPAqTNAxpqbAe80xxIEvWCiwGbBoXoe9bamiPUtWwEE-fFmzXvPvifB4rJ3PtDmHNJwxnjWiql2qPqDkcybh58CmgnF625rnUr25yNZ9XlP1R59jQ562caXOZPDG8fGXaEY9pFPx6S83M8FcIqtMHHGGgw--AmDL8NA7P0yTztU7ZUqyXiHR0f9R_9-1U_uo5Cwvhwb_xbyqMzTw4tGusno-p6-cntmgBdyD08lvzKgSlQIACYybhhfAkttHyh5OmGGWWAcfEHpR26xA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2112956668</pqid></control><display><type>article</type><title>Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C</title><source>ProQuest - Publicly Available Content Database</source><creator>Childs-Kean, Lindsey M ; Jourjy, Jacqueline</creator><creatorcontrib>Childs-Kean, Lindsey M ; Jourjy, Jacqueline</creatorcontrib><description>Chronic hepatitis C is a common cause of liver-related morbidity and mortality. Ledipasvir/sofosbuvir is a combination of 2 direct-acting antiviral agents that has been approved for use in patients with genotype 1, 4, 5, or 6. This approval is based on multiple phase 3 studies in which the rate of sustained virologic response exceeded 90% for 12 or 24 weeks of treatment, depending on the patient population. For some patients, the addition of ribavirin is required. Ledipasvir/sofosbuvir is well tolerated, with the most commonly reported adverse events being fatigue and headaches.</description><identifier>ISSN: 1179-559X</identifier><identifier>EISSN: 1179-559X</identifier><identifier>DOI: 10.1177/1179559X17719125</identifier><language>eng</language><publisher>London, England: Libertas Academica</publisher><subject>Antiviral drugs ; Authorship ; Dosage and administration ; Drug dosages ; Drug therapy ; Genotype &amp; phenotype ; Hepatitis ; Hepatitis C ; Hepatitis C virus ; HIV ; Human immunodeficiency virus ; Infectious diseases ; Liver diseases ; Patients ; Peer review ; Sofosbuvir ; Studies</subject><ispartof>Clinical Medicine Insights: Therapeutics, 2017-06, Vol.2017 (9), p.1-6-012</ispartof><rights>The Author(s) 2017</rights><rights>COPYRIGHT 2017 Sage Publications Ltd. (UK)</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a456t-3d89e9c752ab32f305cccc07e7cb02b920e5eed323fa77a33dd18c42a04457313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2112956668?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>313,314,780,784,792,25753,27922,27924,27925,37012,44590</link.rule.ids></links><search><creatorcontrib>Childs-Kean, Lindsey M</creatorcontrib><creatorcontrib>Jourjy, Jacqueline</creatorcontrib><title>Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C</title><title>Clinical Medicine Insights: Therapeutics</title><description>Chronic hepatitis C is a common cause of liver-related morbidity and mortality. Ledipasvir/sofosbuvir is a combination of 2 direct-acting antiviral agents that has been approved for use in patients with genotype 1, 4, 5, or 6. This approval is based on multiple phase 3 studies in which the rate of sustained virologic response exceeded 90% for 12 or 24 weeks of treatment, depending on the patient population. For some patients, the addition of ribavirin is required. Ledipasvir/sofosbuvir is well tolerated, with the most commonly reported adverse events being fatigue and headaches.</description><subject>Antiviral drugs</subject><subject>Authorship</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Genotype &amp; phenotype</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Infectious diseases</subject><subject>Liver diseases</subject><subject>Patients</subject><subject>Peer review</subject><subject>Sofosbuvir</subject><subject>Studies</subject><issn>1179-559X</issn><issn>1179-559X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9UVGL1DAQLqLgcd67jwXBt95NkiZtHhSORT1hQcETfAvTdHqbo23WJCv4703p4d4eYgKZL1--bybJFMVrBpeMNc1VXrSU-kfGTDMunxVnC1Ut3PNH-GVxEeM9AHBeKyX0WfFuS73bY_zlwtU3P_jYHTIs3VymHZW3gTBNNKfSD-VmF_zsbHlDe0wuuVhuXhUvBhwjXTzE8-L7xw-3m5tq--XT5831tsJaqlSJvtWkbSM5doIPAqTNAxpqbAe80xxIEvWCiwGbBoXoe9bamiPUtWwEE-fFmzXvPvifB4rJ3PtDmHNJwxnjWiql2qPqDkcybh58CmgnF625rnUr25yNZ9XlP1R59jQ562caXOZPDG8fGXaEY9pFPx6S83M8FcIqtMHHGGgw--AmDL8NA7P0yTztU7ZUqyXiHR0f9R_9-1U_uo5Cwvhwb_xbyqMzTw4tGusno-p6-cntmgBdyD08lvzKgSlQIACYybhhfAkttHyh5OmGGWWAcfEHpR26xA</recordid><startdate>20170630</startdate><enddate>20170630</enddate><creator>Childs-Kean, Lindsey M</creator><creator>Jourjy, Jacqueline</creator><general>Libertas Academica</general><general>SAGE Publishing</general><general>SAGE Publications</general><general>Sage Publications Ltd. (UK)</general><general>Sage Publications Ltd</general><scope>188</scope><scope>AFRWT</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AYAGU</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170630</creationdate><title>Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C</title><author>Childs-Kean, Lindsey M ; Jourjy, Jacqueline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a456t-3d89e9c752ab32f305cccc07e7cb02b920e5eed323fa77a33dd18c42a04457313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antiviral drugs</topic><topic>Authorship</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Genotype &amp; phenotype</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Infectious diseases</topic><topic>Liver diseases</topic><topic>Patients</topic><topic>Peer review</topic><topic>Sofosbuvir</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Childs-Kean, Lindsey M</creatorcontrib><creatorcontrib>Jourjy, Jacqueline</creatorcontrib><collection>Airiti Library</collection><collection>Sage Journals GOLD Open Access 2024</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Australia &amp; New Zealand Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Clinical Medicine Insights: Therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Childs-Kean, Lindsey M</au><au>Jourjy, Jacqueline</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C</atitle><jtitle>Clinical Medicine Insights: Therapeutics</jtitle><date>2017-06-30</date><risdate>2017</risdate><volume>2017</volume><issue>9</issue><spage>1</spage><epage>6-012</epage><pages>1-6-012</pages><issn>1179-559X</issn><eissn>1179-559X</eissn><abstract>Chronic hepatitis C is a common cause of liver-related morbidity and mortality. Ledipasvir/sofosbuvir is a combination of 2 direct-acting antiviral agents that has been approved for use in patients with genotype 1, 4, 5, or 6. This approval is based on multiple phase 3 studies in which the rate of sustained virologic response exceeded 90% for 12 or 24 weeks of treatment, depending on the patient population. For some patients, the addition of ribavirin is required. Ledipasvir/sofosbuvir is well tolerated, with the most commonly reported adverse events being fatigue and headaches.</abstract><cop>London, England</cop><pub>Libertas Academica</pub><doi>10.1177/1179559X17719125</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1179-559X
ispartof Clinical Medicine Insights: Therapeutics, 2017-06, Vol.2017 (9), p.1-6-012
issn 1179-559X
1179-559X
language eng
recordid cdi_proquest_journals_2112956668
source ProQuest - Publicly Available Content Database
subjects Antiviral drugs
Authorship
Dosage and administration
Drug dosages
Drug therapy
Genotype & phenotype
Hepatitis
Hepatitis C
Hepatitis C virus
HIV
Human immunodeficiency virus
Infectious diseases
Liver diseases
Patients
Peer review
Sofosbuvir
Studies
title Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A25%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ledipasvir/Sofosbuvir%20in%20the%20Treatment%20of%20Chronic%20Hepatitis%20C&rft.jtitle=Clinical%20Medicine%20Insights:%20Therapeutics&rft.au=Childs-Kean,%20Lindsey%20M&rft.date=2017-06-30&rft.volume=2017&rft.issue=9&rft.spage=1&rft.epage=6-012&rft.pages=1-6-012&rft.issn=1179-559X&rft.eissn=1179-559X&rft_id=info:doi/10.1177/1179559X17719125&rft_dat=%3Cgale_proqu%3EA498584452%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a456t-3d89e9c752ab32f305cccc07e7cb02b920e5eed323fa77a33dd18c42a04457313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2112956668&rft_id=info:pmid/&rft_galeid=A498584452&rft_airiti_id=P20160603001_201712_201808230015_201808230015_1_6_012&rft_sage_id=10.1177_1179559X17719125&rfr_iscdi=true